These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34431439)

  • 1. Need for a risk-based control strategy for managing glycosylation profile for biosimilar products.
    Rathore A; Malani H
    Expert Opin Biol Ther; 2022 Feb; 22(2):123-131. PubMed ID: 34431439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to control therapeutic antibody glycosylation during bioprocessing: Synthesis and separation.
    Edwards E; Livanos M; Krueger A; Dell A; Haslam SM; Mark Smales C; Bracewell DG
    Biotechnol Bioeng; 2022 Jun; 119(6):1343-1358. PubMed ID: 35182428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
    Joshi S; Rathore AS
    BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®.
    Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR
    Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications.
    Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V
    Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
    D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
    Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of high mannose levels in N-linked glycosylation through cell culture process conditions to increase antibody-dependent cell-mediated cytotoxicity activity for an antibody biosimilar.
    Rameez S; Gowtham YK; Nayar G; Mostafa SS
    Biotechnol Prog; 2021 Sep; 37(5):e3176. PubMed ID: 34021724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products.
    Kwon O; Joung J; Park Y; Kim CW; Hong SH
    Biologicals; 2017 Jul; 48():101-108. PubMed ID: 28495312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
    Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
    Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple-parallel-protease digestion coupled with high-resolution mass spectrometry: An approach towards comprehensive peptide mapping of therapeutic mAbs.
    Pradhan G; Sneha JM; Sonwane BP; Santhakumari B; Rao A; Kulkarni MJ
    J Proteomics; 2021 Feb; 232():104053. PubMed ID: 33238212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development.
    Calvo B; Zuñiga L
    Curr Med Chem; 2012; 19(26):4445-50. PubMed ID: 22978327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taking the individual bias out of examining comparability of biosimilars: A case study on monoclonal antibody therapeutics.
    Rathore AS; Joshi S; Nupur N; Saxena N; Bhattacharya S; Roy S
    Int J Biol Macromol; 2023 Feb; 227():124-133. PubMed ID: 36529216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-attribute method (MAM) to assess analytical comparability of adalimumab biosimilars.
    Millán-Martín S; Jakes C; Carillo S; Bones J
    J Pharm Biomed Anal; 2023 Sep; 234():115543. PubMed ID: 37385093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From bioequivalence to biosimilars: How much do regulators dare?
    Weise M
    Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques.
    Ayoub D; Jabs W; Resemann A; Evers W; Evans C; Main L; Baessmann C; Wagner-Rousset E; Suckau D; Beck A
    MAbs; 2013; 5(5):699-710. PubMed ID: 23924801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
    Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
    MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoengineered antibodies: towards the next-generation of immunotherapeutics.
    Mastrangeli R; Palinsky W; Bierau H
    Glycobiology; 2019 Mar; 29(3):199-210. PubMed ID: 30289453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
    Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
    MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.